Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Settles Proxy Contest; Revises Slate of Board Nominees

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics today said that it has settled a proxy contest with institutional investor Special Situations Fund and its affiliates, which will result in a new slate of nominees for the firm's board of directors.

The Los Angeles-based molecular diagnostics firm said that under the terms of the settlement, SSF has agreed to terminate its proxy solicitation and to vote for a revised slate of director nominees. That revised slate will include two outside directors previously nominated by SSF.

The nine nominees to be recommended for election at the 2010 annual meeting of shareholders are Response Genetics President and CEO Kathleen Danenberg, Kirk Calhoun, Gary Nusbaum, Michael Serruya, David Smith, Jan Fagerberg, Michael Metzger, Richard van den Broek, and David Wurzer. Van den Broek and Wurzer were the two previous nominees of SSF.

Response Genetics said that it has postponed its scheduled 2010 annual meeting in order to implement terms of the settlement. A date for the rescheduled meeting will be announced in the near future, said Response Genetics.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.